Breakthrough Columbia University RNA Therapy Uses Skeletal Muscle to Manufacture Heart Regrowing Medicine Following Myocardial Infarction

Columbia University researchers unveil a self-amplifying RNA injection that turns muscle cells into a factory for heart-repairing hormones.

By: AXL Media

Published: Mar 15, 2026, 6:47 AM EDT

Source: Information for this report was sourced from Columbia University School of Engineering and Applied Science

Revolutionizing Cardiac Regeneration via Indirect Delivery

The inability of the adult human heart to regenerate muscle tissue after a heart attack has long been a primary driver of chronic heart failure. According to Ke Cheng, the Alan L. Kaganov Professor of Biomedical Engineering at Columbia, current medical interventions can restore blood flow but cannot replace dead cells. A new study reveals a transformative approach that avoids direct cardiac intervention entirely, instead utilizing a single injection into the thigh or arm. This method allows clinicians to avoid opening the chest or navigating wires through the vascular system, relying instead on the body’s own biological machinery to distribute healing agents.

Learning from the Regenerative Power of Newborns

The biological foundation of this therapy stems from observations of neonatal mammals, which possess a fleeting ability to repair heart tissue immediately after birth. This natural healing is driven by atrial natriuretic peptide, or ANP, a hormone that reduces inflammation and encourages the growth of new blood vessels. Cheng’s team discovered that while newborn hearts experience a massive surge in the gene responsible for ANP after injury, adult hearts fail to produce an adequate amount to facilitate repair. By supplementing this naturally occurring molecule, the researchers aim to restore a "youthful" regenerative capacity to aging or damaged adult hearts.

Solving the Challenge of Cardiac Drug Accumulation

Delivering medication specifically to the heart is notoriously difficult because the organ lacks the natural accumulation mechanisms found in the liver or lungs. Historically, this has forced medical professionals to use invasive infusions or direct injections into the pericardium. To overcome this, the Columbia team engineered RNA-lipid nanoparticles that target skeletal muscle cells. These cells act as a production hub for pro-ANP, an inactive precursor molecule that circulates safely through the bloodstream without reacting with other tissues, solving the problem of drug degradation and systemic side effects.